PT742011E - Preparacao que pode ser absorvida por via percutanea - Google Patents

Preparacao que pode ser absorvida por via percutanea

Info

Publication number
PT742011E
PT742011E PT95938025T PT95938025T PT742011E PT 742011 E PT742011 E PT 742011E PT 95938025 T PT95938025 T PT 95938025T PT 95938025 T PT95938025 T PT 95938025T PT 742011 E PT742011 E PT 742011E
Authority
PT
Portugal
Prior art keywords
preparation
percutaneous
absorbed
skin penetration
percutaneously absorbable
Prior art date
Application number
PT95938025T
Other languages
English (en)
Inventor
Kaneto Uekama
Tetsumi Irie
Michio Hara
Yasuhide Horiuchi
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PT742011E publication Critical patent/PT742011E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT95938025T 1994-11-17 1995-11-16 Preparacao que pode ser absorvida por via percutanea PT742011E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28379394 1994-11-17

Publications (1)

Publication Number Publication Date
PT742011E true PT742011E (pt) 2002-10-31

Family

ID=17670220

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95938025T PT742011E (pt) 1994-11-17 1995-11-16 Preparacao que pode ser absorvida por via percutanea

Country Status (15)

Country Link
US (1) US5854281A (pt)
EP (1) EP0742011B1 (pt)
JP (1) JP4024852B2 (pt)
KR (1) KR100413202B1 (pt)
CN (1) CN1102850C (pt)
AT (1) ATE220911T1 (pt)
AU (1) AU713461B2 (pt)
CA (1) CA2181364A1 (pt)
DE (1) DE69527507T2 (pt)
ES (1) ES2180658T3 (pt)
FI (1) FI962869A (pt)
NO (1) NO962972L (pt)
PT (1) PT742011E (pt)
TW (1) TW413637B (pt)
WO (1) WO1996015793A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0925788A4 (en) * 1997-03-13 1999-12-01 Toray Industries MEDICINES FOR TREATING DIABETIC VASCULAR INJURIES
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
US6448251B1 (en) * 1997-11-28 2002-09-10 Peter T. Pugliese Zwitterionic-fatty acid compounds having anti-inflammatory properties
PL345087A1 (en) * 1998-06-25 2001-12-03 Lavipharm Lab A device and method for the treatment of erectile dysfunction
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1242012B1 (en) * 1999-11-24 2009-12-30 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
EP1390073A2 (en) * 2001-05-03 2004-02-25 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
KR101187693B1 (ko) * 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
CA2552887A1 (en) * 2004-01-14 2005-07-28 Lavipharm Laboratories, Inc. Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
EP1878429B1 (en) * 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
WO2009137078A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US20130274352A1 (en) * 2009-04-14 2013-10-17 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
CA2784120A1 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
JP5878715B2 (ja) * 2011-09-22 2016-03-08 久光製薬株式会社 貼付剤
US9457012B2 (en) 2012-03-22 2016-10-04 Teikoku Seiyaku Co., Ltd. Transdermal absorption preparation
JP6444305B2 (ja) * 2013-08-09 2018-12-26 帝國製薬株式会社 ベラプロスト含有貼付剤
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
CN110139641B (zh) * 2016-12-28 2022-09-09 富士胶片富山化学株式会社 外用组合物
WO2023240105A1 (en) * 2022-06-07 2023-12-14 Biomimetix Jv, Llc Hydrophobic compositions including a hydrophilic active ingredient and methods relating thereto

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
DE3779999T2 (de) * 1986-11-14 1992-12-10 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
JPH02503672A (ja) * 1987-06-01 1990-11-01 ワーナー‐ランバート・コンパニー 水性の系における浸透促進剤としての脂肪酸およびその短鎖エステル
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
JP2503672B2 (ja) 1989-07-28 1996-06-05 井関農機株式会社 草刈機の刈草収容装置
JPH0737389B2 (ja) * 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンe1含有の軟膏剤
JP2838297B2 (ja) * 1989-11-02 1998-12-16 日産化学工業株式会社 コルヒチン含有外用剤
JPH082801B2 (ja) * 1989-11-09 1996-01-17 株式会社資生堂 経皮吸収促進剤及び皮膚外用剤
JP3243564B2 (ja) * 1990-08-20 2002-01-07 リードケミカル株式会社 外用貼付剤
JP3059204B2 (ja) * 1990-10-25 2000-07-04 帝國製薬株式会社 安定なプロスタグランジンi▲下1▼類含有皮膚適用組成物
JPH04243827A (ja) * 1991-01-25 1992-08-31 Sumitomo Pharmaceut Co Ltd プロスタグランジン誘導体含有溶解型軟膏剤
DE4124693A1 (de) * 1991-07-22 1993-01-28 Schering Ag Carbacyclinderivate als mittel zur behandlung von vitiligo
DE4124695C2 (de) * 1991-07-22 1994-12-22 Blitstein Willinger Eveline Dr Verwendung von Carbacyclinderivaten zur Behandlung von Psoriasis vulgaris
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
JP3115482B2 (ja) * 1994-01-28 2000-12-04 帝人株式会社 プロスタサイクリン類含有皮膚適用組成物

Also Published As

Publication number Publication date
DE69527507D1 (de) 2002-08-29
CN1140412A (zh) 1997-01-15
EP0742011B1 (en) 2002-07-24
EP0742011A4 (en) 1997-08-20
TW413637B (en) 2000-12-01
AU713461B2 (en) 1999-12-02
EP0742011A1 (en) 1996-11-13
AU3881195A (en) 1996-06-17
US5854281A (en) 1998-12-29
CA2181364A1 (en) 1996-05-30
ATE220911T1 (de) 2002-08-15
WO1996015793A1 (fr) 1996-05-30
NO962972D0 (no) 1996-07-16
NO962972L (no) 1996-09-16
CN1102850C (zh) 2003-03-12
DE69527507T2 (de) 2002-11-07
KR100413202B1 (ko) 2004-04-13
ES2180658T3 (es) 2003-02-16
JP4024852B2 (ja) 2007-12-19
FI962869A0 (fi) 1996-07-16
FI962869A (fi) 1996-09-16

Similar Documents

Publication Publication Date Title
PT742011E (pt) Preparacao que pode ser absorvida por via percutanea
US5326566A (en) Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5391548A (en) Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris
US5326790A (en) Administration of skin medications by use of dicarboxylic acids and derivatives
IE940583L (en) Topical antimicrobial pharmaceutical compositions
EE9500063A (et) Farmatseutilised liposoomsüstepreparaadid
WO1994013257A1 (en) Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
JPH085785B2 (ja) 魚鱗癬の治療剤
FR2715565B1 (fr) Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
DK0582239T3 (da) Farmaceutisk og/eller kosmetisk formulering
ES2204552T3 (es) Metodo y composicion para tratar el acne.
NO177774C (no) Fremgangsmåte for fremstilling av et preparat egnet for tilförsel av en hovedsakelig vannuopplöslig aktiv bestanddel
ATE127683T1 (de) Stabile emulgierte tretinoin-cremeformulierungen.
KR950000141A (ko) 피부병 치료용 약제조성물 제조를 위한 방향족산을 함유한 l- 카르니틴 o-에스테르의 용도
IE810489L (en) Composition for topical application
ES2091981T3 (es) Procedimiento para la fabricacion de preparaciones de crema estables, hidrofilas o ambifilas, que contienen componentes vesiculares, asi como el uso de las mismas.
DK0416804T3 (da) Præparat til udvortes administration
IL96903A0 (en) Topical pharmaceutical compositions comprising a vitamin d3 derivative
JPH03120230A (ja) 薬効成分の経皮吸収促進剤及び経皮吸収型製剤
EP0302836A1 (en) Pharmaceutical compositions for topical use containing miocamycin
US4873266A (en) Menthone enhancement of transdermal drug delivery
KR890701098A (ko) 히드로퀴논 및 코지산을 함유하는 제약 또는 화장제 조성물
NO971879L (no) Preparat for transdermal administrasjon
EP0685230A4 (en) STABLE DERMATOLOGICAL PREPARATIONS CONTAINING MYCOHENOLIC ACID.
SK18652000A3 (sk) Farmaceutická kompozícia na báze erytromycínových solí mastných kyselín s 12 až 22 atómami uhlíka vo zvyšku mastnej kyseliny a použitie týchto erytromycínových solí mastných kyselín na topické liečenie kožných ochorení